Table 3.
Adverse events subsequent to high dose melphalan
| Body system | Grade 3 | Grade 4 | Any 3–5 |
|---|---|---|---|
| Bone marrow myelosuppression | 0 | 45 | 45 |
| Anemia | 30 | 1 | 31 |
| Neutropenia | 0 | 45 | 45 |
| Thrombocytopenia | 22 | 23 | 45 |
| Gastrointestinal | 13 | 18 | 31 |
| Allergy/Immunologic | 0 | 1 | 1 |
| Cardiovascular | 4 | 0 | 4 |
| Constitutional | 2 | 0 | 2 |
| Dermatologic | 0 | 0 | 0 |
| Hemorrhage | 13 | 0 | 13 |
| Hepatic | 1 | 0 | 1 |
| Infection/febrile neutropenia | 33 | 0* | 35* |
| Metabolic/laboratory | 17 | 0 | 17 |
| Neurology | 4 | 0 | 4 |
| Pain | 2 | 0 | 2 |
| Pulmonary | 2 | 1* | 3* |
| Renal | 1 | 0 | 1 |
Any grade 3–5 adverse events (CTC 2.0) subsequent to high dose melphalan regardless of attribution, maximum grade per organ system per patient
*
There was an additional patient who died of CMV pneumonitis.